31 unknown, 28 completed, 13 recruiting, 5 not yet recruiting. 22 Not applicable, 22 Phase 2, 12 Phase 1, 12 Phase 3, 8 Phase 4.
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety | Phase 2 | Not yet recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 60 | 2028-05-25 | 2025-11-25 |
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH Tamsulosin 0.4 mg + Tadalafil 2.5 mg, Tamsulosin 0.4 mg + Tadalafil 5 mg, Tamsulosin 0.4 mg - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 90 | 2026-07-01 | 2026-07-23 |
| Safety and Efficacy of Papillary Versus NonPapillary Access During Percutaneous Nephrolithotomy Papillary access puncture, Non-papillary access puncture - Safety, Efficacy | Not applicable | Recruiting | Ain Shams University | 70 | 2025-11-01 | 2026-10-02 |
| Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy - Efficacy, Safety | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 132 | 2025-09-29 | 2025-08-19 |
| Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells - Spinal Cord Injury, Safety | Phase 1 | Recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 12 | 2025-07-02 | 2025-11-25 |
| Bilateral Peribulbar Block for Cataract Surgery Bilateral peribulbar block - Safety, Efficacy | Completed | Tanta University | 50 | 2025-06-03 | 2026-04-24 | |
| Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Recruiting | Anhui Provincial Hospital | 100 | 2025-03-11 | 2026-10-28 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer Neoadjuvant therapy + vitamin D2, Neoadjuvant therapy - Vitamin D, Neoadjuvant Therapy | Not applicable | Recruiting | Jiuda Zhao | 140 | 2024-10-18 | 2025-01-17 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy - Efficacy | Phase 1 / Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 150 | 2024-10-01 | 2024-10-09 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses - Children With Myopia, Treatment | Not applicable | Recruiting | Beijing Tongren Hospital | 120 | 2024-08-02 | 2026-01-07 |
| Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency Niraparib - Efficacy | Phase 2 | Not yet recruiting | Korea University Anam Hospital | 33 | 2024-02-27 | 2024-02-01 |
| Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma Induction Immunotherapy-Toripalimab, Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Efficacy | Phase 2 | Completed | Sun Yat-sen University | 170 | 2024-02-15 | 2026-08-03 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency Heart Failure, Levosimendan | Unknown | Yi Han | 1600 | 2023-11-16 | 2024-01-16 | |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative | Phase 2 | Unknown | Lin Chen | 80 | 2023-10-01 | 2024-02-29 |
| Study of the Clinical Benefits of Different Formulations of Amphotericin B Efficacy, Safety | Unknown | Qianfoshan Hospital | 184 | 2023-09-01 | 2024-10-17 |
Showing 20 of 80. Sign in to see all of them.
Drug-Related Side Effects and Adverse Reactions (3) · Heart Failure (3) · Breast Neoplasms (2) · Chondrosarcoma (2) · Diabetes Mellitus, Type 2 (2) · Schizophrenia (2) · Spinal Cord Injuries (2) · Agnosia (1) · Alzheimer Disease (1) · Anxiety Disorders (1) · Arthritis, Rheumatoid (1) · Asthma (1) · COVID-19 (1) · Calciphylaxis (1) · Carcinoma, Non-Small-Cell Lung (1)
Neoplasms (14) · Neoplasms by Site (10) · Neoplasms by Histologic Type (8) · Pathological Conditions, Signs and Symptoms (7) · Urogenital Diseases (7) · Skin and Connective Tissue Diseases (6) · Cardiovascular Diseases (5) · Digestive System Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Nervous System Diseases (5) · Skin Diseases (5) · Central Nervous System Diseases (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4)
apatinib (3) · Bevacizumab (2) · Cisplatin (2) · Deoxycholic Acid (2) · Gemcitabine (2) · Radiosurgery (2) · Standard of Care (2) · 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Adalimumab (1) · Albuterol (1) · Anesthesia, General (1) · Capecitabine (1) · Cataract Extraction (1) · Chloroquine (1) · Control Groups (1)
Ain Shams University (3) · Sichuan Huiyu Pharmaceutical Co., Ltd (3) · ARJ Medical, Inc. (2) · Anhui Provincial Hospital (2) · Korea University Anam Hospital (2) · Kythera Biopharmaceuticals (2) · Peking University People's Hospital (2) · Shanghai Juncell Therapeutics (2) · Stemirna Therapeutics (2) · Sun Yat-sen University (2) · Tanta University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (2) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Yi Han (2)
China (34) · Egypt (7) · United States (6) · South Korea (5) · Belgium (2) · Brazil (2) · Laos (2) · Bangladesh (1) · Bulgaria (1) · Denmark (1) · Ethiopia (1) · Germany (1) · Hong Kong (1) · Israel (1) · Italy (1)
Abdelrahman G Salman, MD (2) · Elie Fiss (2) · Frederick Beddingfield, III, MD, PhD (2) · Limin Rong, prof and M.D (2) · Mayfong Mayxay, doctor (2) · Yi Han, doctorate (2) · Abbey B Berenson, MD, PhD (1) · Adina Popa, Prof PharmD (1) · Ana Afonso (1) · Andrea Ludwig-Sengpiel, Dr. (1) · Anne-Marie Kirsten, Dr. (1) · Anneliese Linnhoff, Dr. med. (1) · Bethany E Karl, DO (1) · Bockretsion Gidey (1) · Christine Grigat, Dr. (1)
PMID 17870045, PMID 21383283, PMID 22415477, PMID 23075681, PMID 26188037, PMID 27501767, PMID 28111294, PMID 29476349, PMID 30528370, PMID 30777086, PMID 32033600, PMID 32547189, PMID 33299558, PMID 33538338, PMID 33552517, PMID 34336132, PMID 34407054, PMID 35142858, PMID 35412950, PMID 35533793, PMID 36595042, PMID 36892220, PMID 37305429, PMID 38169790, PMID 38320488, PMID 38430085, PMID 39234636, PMID 39382852, PMID 40097288, PMID 40518559, PMID 40693391, PMID 41276263, PMID 42419896
2018 (2), 2014 (1)